A Study of Tocilizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARDs: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for A Study of Tocilizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARDs (NCT00810277), a na phase 3 study. The primary outcome is Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs).

2. Clinical Question

The clinical question is therefore descriptive: it concerns the proportion of participants in this study group who experienced adverse events during the stated follow-up period. It does not ask whether tocilizumab changed risk relative to another group, because no concurrent comparator was included. Nor does the primary outcome directly measure improvement in rheumatoid arthritis disease activity. The listed secondary outcomes indicate that disease activity and laboratory measures were part of the study’s outcome set, but their numerical results and analyses are not reported in the registry record.

The study concerned people whose response to current non-biologic DMARDs was inadequate. That defines the population of interest, but the record does not provide further eligibility details or participant characteristics. The open-label, single-group design can describe experiences among participants receiving the study treatment, while leaving treatment effects relative to an alternative uncertain. Any interpretation should keep that distinction between a safety description and a comparative treatment estimate in view.

3. Trial Design

This was a Phase 3, single-group, open-label study of tocilizumab in rheumatoid arthritis. The registry lists enrollment of 14 participants, no masking, and allocation as not applicable. It was marked completed. The record gives a start date of 2008-11-30 and a primary completion date of 2010-05-26.

The study summary describes intravenous tocilizumab at 8mg/kg every 4 weeks for a total of 6 infusions. Participants could receive it as monotherapy or with their current non-biologic DMARDs. The title and summary identify the intended population as people with active rheumatoid arthritis and an inadequate response to current non-biologic DMARDs. The primary outcome covered baseline up to Week 24.

Because there was only one treatment group, the design does not provide a randomized or concurrent control comparison. The open-label designation means masking was absent; the record does not describe further procedures for outcome assessment. There is no arm description beyond the single group’s intervention, and the record does not report details such as adherence, treatment exposure, or reasons for any individual participant’s treatment choices.

The registry lists several secondary outcomes, including disease activity, DAS28 remission, ACR20, ACR50 and ACR70 response, C-reactive protein, erythrocyte sedimentation rate, discontinuation, and elevations in liver enzymes and lipids. It does not provide numerical findings for these outcomes in the posted record. The record also does not report the protocol’s rationale for its enrollment target or a statistical analysis plan. These omissions limit conclusions about design intentions and about outcomes beyond the primary safety measure.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Analysis population included all participants who entered the study.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Analysis population included all participants who entered the study.

6. Primary Endpoint

The registry lists the primary outcome as Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs), measured over Baseline up to Week 24.

The primary endpoint is the percentage of participants with adverse events or serious adverse events from baseline up to Week 24. It uses the participants who entered the study as its analysis population. An adverse event was defined as an untoward medical occurrence in a participant who received study drug, without regard to whether it might have been caused by treatment. Serious adverse events were defined by outcomes or significance criteria including death, initial or prolonged inpatient hospitalization, a life-threatening experience, persistent or significant disability or incapacity, or congenital anomaly. The registry specifies that adverse events include serious and non-serious events.

This type of endpoint is used to describe how many participants experienced an event during a defined period, rather than to measure disease activity. Reporting the percentage makes the participant-level frequency interpretable as a proportion of the study group, while the follow-up window clarifies the period to which the summary applies. It does not, by itself, establish that treatment caused an event. Events are counted regardless of whether a causal relationship is considered possible, and a single-group design cannot estimate how event frequency would have differed under a comparator.

The posted results report 1 participant with a serious adverse event among 14 at risk and 13 participants with other adverse events among 14 at risk. Erysipelas is listed among the serious adverse event terms at 7.1%. The record does not report a death count. These figures describe participants in this study; they do not establish comparative risk or characterize the full range of possible events beyond what the registry record reports.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The primary outcome is a proportion: the number of participants meeting an event definition relative to the number at risk. For this study, the registry reports 1 participant with a serious adverse event among 14 at risk and 13 participants with other adverse events among 14 at risk. The accompanying serious adverse event term erysipelas is reported at 7.1%. These summaries describe participants, rather than the total number of event episodes. The registry does not give episode counts or additional detail about the timing of individual events.

What a proportion describes

General statistical explanation: a proportion summarizes how common an outcome was in a defined group over a defined observation period. Its meaning depends on the numerator, the group included in the denominator, and the outcome definition. Here, the primary safety population is described as all participants who entered the study, and the outcome window is baseline up to Week 24. The reported at-risk counts are 14 for each of the two safety categories.

A proportion is not the same as a rate. A rate would use person-time or another measure of time at risk in its denominator. The registry gives participant counts and a fixed endpoint window, not person-time-based estimates. Nor should the two reported safety categories be added to create a count of unique participants: the record does not give the overlap between participants with serious and other adverse events, and serious events are included in the registry’s broad adverse event definition.

What uncertainty means

General statistical explanation: a confidence interval describes uncertainty around an estimated quantity under the assumptions of a statistical method. A narrow interval indicates greater precision than a wide interval, but an interval cannot correct for a design that lacks a comparator. For a single-group event proportion, uncertainty concerns the estimate for a population represented by the study group; it does not show what would have happened under a different treatment. The registry record does not report confidence intervals for the primary safety results.

When the number of participants is small, estimates can be sensitive to the outcomes of individual participants. That is a general property of proportions with small denominators. It is relevant to interpreting these results because the reported at-risk group contains 14 participants. The record does not report an uncertainty interval or a statistical test that would quantify precision in a particular way.

Why the design matters

General statistical explanation: randomization can help balance measured and unmeasured participant characteristics between treatment groups, while a concurrent control group provides a reference outcome under an alternative condition. Neither feature creates a perfect comparison, but together they support comparative inference. This study was single-group and open label, with allocation listed as not applicable. It therefore supplies no concurrent control estimate. Differences from external experience, if considered, would require assumptions and information not reported in the registry record.

Open-label studies do not mask treatment assignment. That design feature can matter for reporting, observation, and assessment, depending on the outcome and study procedures. The registry does not describe additional safeguards or outcome-assessment methods. The primary endpoint uses adverse events defined without regard to a possible causal relationship, but the record does not provide further detail about event collection or adjudication.

Over-dispersion and outcome type

General statistical explanation: over-dispersion arises when observed variability is greater than a statistical model expects. It is especially relevant to some count outcomes, where a basic model may assume that the mean and variance have a particular relationship. A model that does not allow enough variability can produce confidence intervals that are too narrow or tests that appear more certain than warranted. The primary outcome is reported as a percentage of participants with an event, rather than as a modeled count outcome. The registry record does not report an over-dispersion assessment or a statistical model for this endpoint, so there is no basis to state that one was used.

Planning illustrations are not observed power

The registry record gives assumptions for planning illustrations based on an observed effect: a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation, with the effect to detect expressed as a fraction of the observed effect. These are planning assumptions, not a description of this trial’s single-group design. The record does not report the trial’s own sample-size justification. Any sample-size illustration under those assumptions is not the study’s observed power. Observed power is not a substitute for an uncertainty interval around the results, and an illustration does not change the fact that this study had no comparator.

In general, sample-size calculations depend on the outcome, the target effect, the variability or event frequency, the chosen error thresholds, and the design. Since the registry record does not report a protocol justification or a statistical analysis plan, the rationale for enrolling 14 participants is not reported in the registry record. The listed planning assumptions should not be mistaken for the protocol’s original enrollment rationale.

Analyses and recalculation

The registry record lists 0 analyses. It does not report a formal inferential analysis for the primary outcome, a confidence interval, or adjusted or unadjusted comparisons. There are no comparative arms from which to estimate a treatment contrast. The posted safety counts can be read descriptively as recorded; any recalculated summary would not replace a sponsor analysis. If a discrepancy between a sponsor analysis and a simple recalculation were reported, the sponsor’s own analysis would take precedence. The registry record does not report such a discrepancy for these results.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists several secondary outcomes: DAS28, DAS28 remission, ACR20, ACR50 and ACR70 response, CRP, ESR, discontinuation, ALT or AST elevations, and lipid elevations. It does not report numerical results for these outcomes in the posted record. It also does not report whether the protocol specified a hierarchy among outcomes, adjusted for multiple comparisons, or used a particular approach to control the chance of false-positive findings across tests. Multiplicity procedures are not reported in the registry record.

Missing-data handling is also not reported in the registry record. The record does not say how missing outcome measurements, withdrawals, or incomplete follow-up were treated in any analysis. The primary safety population is described as all participants who entered the study, and the reported at-risk counts are 14 for both serious and other adverse events. Those details do not establish how any missing data were handled for secondary outcomes.

The registry lists 0 analyses and does not provide a statistical analysis plan. It is therefore not possible to determine from the posted record which statistical tests, models, or adjustment procedures were planned or performed for the listed outcomes. The absence of reported multiplicity and missing-data methods is a limitation in interpreting results, particularly for outcomes that are not presented. It does not imply that a particular procedure was or was not used outside the information recorded.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: erysipelas (7.1%).

The serious adverse event result is 1 participant among 14 at risk. The registry lists erysipelas at 7.1% among the serious adverse event terms. The broader category of other adverse events includes 13 participants among 14 at risk. The record does not report a death count. These are descriptive findings over baseline up to Week 24, not a comparison with another treatment group.

A serious adverse event is defined by specified consequences, such as death, hospitalization, a life-threatening experience, persistent or significant disability or incapacity, congenital anomaly, or another reason an event is deemed significant. The registry’s adverse event definition includes occurrences without regard to the possibility of a causal relationship to study drug. Accordingly, the recorded events should not be treated as evidence that the study drug caused them.

The reported participant counts do not convey all details about event timing, duration, recurrence, or clinical course. The registry record does not report those details. Nor does the single-group design show whether these event frequencies differ from what would have occurred under another treatment or without study treatment. The results describe the safety observations recorded among participants in this study, within the stated follow-up window.

12. What the Result Does, and Does Not, Mean

The posted primary result gives a descriptive account of adverse events in a group receiving tocilizumab. It reports 1 participant with a serious adverse event among 14 at risk, 13 participants with other adverse events among 14 at risk, and erysipelas at 7.1% among the serious adverse event terms. The primary outcome covers baseline up to Week 24. These details indicate what was recorded in this study group, using the registry’s stated definitions.

The result does not establish that tocilizumab caused any particular event. The adverse event definition explicitly does not require a possible causal relationship. The result also does not estimate the difference in safety between tocilizumab and another treatment, because the study had no comparator group. A comparison with an outside group would require appropriate data and assumptions not reported in the registry record.

The primary endpoint is a safety outcome, not a direct measure of rheumatoid arthritis activity. Although the registry lists disease activity, remission, ACR responses, and laboratory outcomes, it does not report their numerical findings. The primary safety result therefore cannot be used to describe whether disease activity changed or whether laboratory measurements changed.

Precision is limited by the small enrollment and the lack of a reported confidence interval. A percentage or count from a small study can be uncertain, and the record does not provide an interval or inferential analysis to quantify that uncertainty. The findings also apply to the study’s enrolled participants and the stated follow-up window; the registry record does not provide further participant characteristics for assessing generalizability.

In statistical terms, the result is a description of observed events, not proof of benefit or harm relative to an alternative. It does not establish a causal treatment effect, comparative safety, or the results of outcomes that were listed but not reported. These boundaries are important when reading the safety figures alongside the study’s single-group, open-label design.

13. Why This Trial Matters Statistically

This study is a useful example of the distinction between describing an event frequency and estimating a treatment effect. Its primary outcome records the percentage of participants with adverse events or serious adverse events in a single treated group. Such a description can characterize what was observed during a defined follow-up window, but without a comparator it cannot establish whether event frequency differed from another treatment condition.

The registry’s population and endpoint definitions matter for interpreting the counts. The safety analysis population included all participants who entered the study, and the reported at-risk groups contain 14 participants. Serious adverse events and other adverse events are not interchangeable categories, and adverse events were defined without requiring a causal link to study drug. Those definitions shape what the reported figures mean.

The record also illustrates why missing analysis details matter. It lists secondary disease activity and laboratory outcomes but does not report their numerical findings. It does not report a statistical analysis plan, missing-data procedures, multiplicity handling, confidence intervals, or a sample-size rationale. These absences constrain the conclusions that can be drawn, even when a primary safety summary is available.

Finally, the stated planning assumptions for sample-size illustrations should not be confused with the design of the study itself or with observed power. The trial was single-group, whereas those illustrations assume equal allocation between two arms. Keeping design, analysis, and planning assumptions separate is essential for a careful statistical reading of the record.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal design limitation is the absence of a comparator group. The study can describe adverse events among participants receiving tocilizumab, but it cannot estimate a randomized difference in event frequency relative to another intervention. Allocation is listed as not applicable, and the study is single-group and open label. The record does not report procedures that might address potential effects of unmasked treatment on outcome reporting or assessment.

Enrollment was 14 participants, limiting the amount of information available for estimating event frequencies. The registry record does not report confidence intervals for the primary safety result, so its precision is not quantified in the posted results. The record also does not report the protocol’s sample-size justification, a statistical analysis plan, or the methods used for statistical inference.

The primary outcome is defined broadly, and events were included regardless of whether a causal relationship was considered possible. The record does not provide detailed event-level information about timing, duration, recurrence, or severity beyond the serious-event criteria and listed term. Deaths are not reported in the registry record.

Several secondary outcomes are listed, but their findings are not reported in the registry record. Methods for handling missing observations and multiplicity are also not reported. Further participant characteristics, adherence information, and details about individual treatment exposure are not reported in the registry record. These limits mean that the posted safety counts should be interpreted as a bounded description of this study group, rather than a comprehensive comparative assessment.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: A Study of Tocilizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARDs — NCT00810277.
• Registry record last updated 2017-08-03; status last verified 2017-06.
• Results first posted 2016-03-31.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

This completed Phase 3 study evaluated tocilizumab in participants with active rheumatoid arthritis and an inadequate response to current non-biologic DMARDs. It was open label and single group, with 14 participants enrolled. The study summary describes intravenous tocilizumab at 8mg/kg every 4 weeks for a total of 6 infusions, either alone or alongside current non-biologic DMARDs.

The primary outcome was the percentage of participants with adverse events or serious adverse events from baseline up to Week 24. The registry reports 1 participant with a serious adverse event among 14 at risk and 13 participants with other adverse events among 14 at risk. Erysipelas is listed among serious adverse event terms at 7.1%. A death count is not reported in the registry record.

The registry lists disease activity, response, laboratory, and discontinuation outcomes, but their numerical results are not reported. Comparative effects, analysis methods, missing-data handling, multiplicity procedures, and the protocol’s sample-size rationale are not reported in the registry record. The primary safety findings are descriptive and do not provide a comparison with another treatment.